Cardiovascular Risk in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review
- PMID: 39274386
- PMCID: PMC11396696
- DOI: 10.3390/jcm13175173
Cardiovascular Risk in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review
Abstract
Background/Objectives: A comprehensive and up-to-date review on cardiovascular disease (CVD) risk in patients with COPD is needed. Therefore, we aimed to systematically review the risk of a range of CVD in patients with COPD. Methods: We searched three databases (Pubmed, Web of Science, SCOPUS) from inception to September 2023 using terms related to COPD and CVD. Observational studies were included if they (1) were conducted in adults with a diagnosis of COPD based on the GOLD criteria, spirometry, physician diagnosis, or review of electronic health records; (2) reported the risk of CVD, namely of myocardial infarction (MI), ischaemic heart disease (IHD), atrial fibrillation (AF), heart failure, cerebrovascular disease, pulmonary hypertension, and peripheral vascular disease, compared with a control population using a measure of risk. A narrative synthesis was used. Results: Twenty-four studies from 2015 to 2023, mainly from Europe (n = 17), were included. A total of 3,485,392 patients with COPD (43.5-76.0% male; 63.9-73.5 yrs) and 31,480,333 (40.0-55.4% male, 49.3-70.0 yrs) controls were included. A higher risk of CVD in patients with COPD was evident regarding overall CVD, MI, IHD, heart failure, and angina. Higher risks of arrhythmia and AF, stroke, sudden cardiac death/arrest, pulmonary embolism, pulmonary hypertension, and peripheral vascular disease were also found, although based on a small amount of evidence. Conclusions: Patients with COPD have a higher risk of CVD than the general population or matched controls. This review underscores the need for vigilant and close monitoring of cardiovascular risk in individuals with COPD to inform more precise preventive strategies and targeted interventions to enhance their overall management.
Keywords: cardiopulmonary risk; cardiovascular disease; chronic obstructive pulmonary disease; comorbidities; mortality; myocardial infarction.
Conflict of interest statement
J.C. has received fees for lectures and consultancy from AstraZeneca, BIAL, GSK, and Viatris; R.B. has received speaker or advisory board fees from AstraZeneca, Bayer, Bial, Boehringer Ingelheim, CSL, Daiichi-Sankyo, Janssen, JABA Recordati, Novartis, Pfizer, Servier, and Tecnimede. All other authors have no conflicts of interest to disclose. AstraZeneca participated in the design of this study.
Figures


References
-
- Global Initiative for Chronic Obstructive Lung Disease Global Strategy for Prevention, Diagnosis and Management of Copd: 2024 Report. 2024. [(accessed on 26 August 2024)]. Available online: https://goldcopd.org/2024-gold-report/
-
- Adeloye D., Song P., Zhu Y., Campbell H., Sheikh A., Rudan I. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: A systematic review and modelling analysis. Lancet Respir. Med. 2022;10:447–458. doi: 10.1016/S2213-2600(21)00511-7. - DOI - PMC - PubMed
-
- Safiri S., Carson-Chahhoud K., Noori M., Nejadghaderi S.A., Sullman M.J.M., Heris J.A., Ansarin K., Mansournia M.A., Collins G.S., Kolahi A.-A., et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: Results from the Global Burden of Disease Study 2019. BMJ. 2022;378:e069679. doi: 10.1136/bmj-2021-069679. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources